Clinical trials: Coronary Heart Disease Risk Reduction
Cardiovascular Diseases, Heart Diseases
Reducing Total Cardiovascular Risk in an Urban Community
PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus
- Trial name
- COACH (NCT00241904)
- Testing
- Lifestyle Changes, Antiplatelet Agents, Beta Blocker
- Where
- United States
- Volunteers
- 525 people
- Sponsor
- Johns Hopkins University
Heart Failure, Heart Failure, Systolic
Predicting Heart Failure Outcomes With Biomarkers and Imaging
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BIOPHF (NCT07332520)
- Volunteers
- 4,000 people
- Sponsor
- Xinjiang Medical University
Coronary Artery Disease
Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting
The aim of the project is to demonstrate a fibrinolytic effect of sonothrombolysis (continual transcranial Doppler monitoring) using 2 MHz diagnostic probe on the reduction of risk of brain infarctions due to the activation of…
- Trial name
- NCT02351050
- Testing
- Sonolysis
- Where
- Slovakia
- Volunteers
- 144 people
- Sponsor
- University Hospital Ostrava
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics
Atrial Fibrillation
Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation
This study is being done to see if the addition of mangosteen juice to standard medical care will reduce the risk of atrial fibrillation (AF) recurrence following direct current (DC) cardioversion.
- Trial name
- MRI-AF (NCT00951301)
- Testing
- mangosteen juice
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Mayo Clinic
Heart Failure, Cognitive Impairment
Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor
This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure.
- Conditions
- Heart Failure, Cognitive Impairment, Dementia, Left Ventricular Dysfunction
- Trial name
- Cog-HF (NCT06088212)
- Testing
- Disease management program
- Where
- Australia
- Volunteers
- 168 people
- Sponsor
- Baker Heart and Diabetes Institute
Hypertension, Diabetes
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.
- Trial name
- EFFORT (NCT00829296)
- Testing
- nebivolol, Metoprolol
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Acute Coronary Syndrome
Tirofiban and Enoxaparin in High Risk Coronary Intervention
Patients undergoing coronary angioplasty are frequently treated with new drugs that stop blood platelets working and so improve the success of the procedure. Individual patients may vary in the dose of the drug required.
- Trial name
- NCT00790387
- Testing
- Enoxaparin, Tirofiban, unfractionated heparin
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Prince Charles Hospital
Cardiovascular Risk Factor, Cardiovascular Diseases
Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with CVD, or at high risk for CVD, on a…
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
- Trial name
- LIBerate-HR (NCT04806893)
- Testing
- lerodalcibep
- Where
- 6 sites in United States, India and 1 more
- Volunteers
- 900 people
- Sponsor
- LIB Therapeutics LLC
Cardiovascular Diseases
Cardiovascular Risk Reduction Program Aimed at African American Women (The HHER Lifestyle Program)
Cardiovascular disease (CVD) is a serious health problem among African American women. This study will evaluate a health care center-based program that aims to encourage African American women to eat a low fat diet and increase…
- Trial name
- HHER (NCT00860444)
- Testing
- Basic Educational and Counseling Program, Comprehensive Educational and Counseling Program
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Heart Disease
Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil
The goal is to test the safety and efficacy of an EPA-enriched oil made by DuPont. DuPont wishes to corroborate the safety of its novel oil rich in EPA in humans prior to placing such a dietary supplement on the market.
- Trial name
- EPA (NCT00988585)
- Testing
- EPA 600, EPA 1800, Olive Oil
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Cardiovascular Research Associates
Worksite Health Promotion, Lifestyle Risk Reduction
Intervention to Increase Physical Activity and Wellbeing Among Staff and Residents in Assisted Living Facilities
The purpose of the study is to test a program that aims to help staff increase wellness behaviors and test the impact of this program on staff and work outcomes.
- Conditions
- Worksite Health Promotion, Lifestyle Risk Reduction, Occupational Burnout, Healthcare Workers
- Trial name
- WHHIP+FFC 2026 (NCT07785947)
- Testing
- WHHIP, FFC
- Where
- United States
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Cardiovascular Diseases, Coronary Heart Disease Risk Reduction
Population-Based Modeling of Cholesterol Lowering in the United States
To evaluate the cost-effectiveness of cholesterol-lowering strategies in the United States population. The study used the Coronary Heart Disease (CHD) Policy Model, a state-transition computer simulation model used to obtain…
- Conditions
- Cardiovascular Diseases, Coronary Heart Disease Risk Reduction, Heart Diseases, Coronary Disease
- Trial name
- NCT00005463
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Disease, Cerebrovascular Accident
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients…
- Conditions
- Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
- Trial name
- TNT (NCT00327691)
- Testing
- Atorvastatin
- Where
- 314 sites in United States, Australia and 12 more
- Volunteers
- 8,600 people
- Sponsor
- Pfizer
Coronary Artery Bypass, Myocardial Infarction
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)
The purpose of this study is to determine whether acadesine is effective in reducing the cardiovascular and cerebrovascular adverse events in high-risk participants undergoing CABG surgery.
- Conditions
- Coronary Artery Bypass, Myocardial Infarction, Ventricular Dysfunction, Left, Stroke
- Trial name
- RED-CABG (NCT00872001)
- Testing
- Acadesine, Normal Saline
- Volunteers
- 3,080 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure With Reduced Ejection Fraction
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics.
- Trial name
- NCT07490067
- Testing
- Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Cardiovascular Disease
Heart Health Buddies: Peer Support to Decrease CVD Risk
This pilot study will use a hybrid reciprocal peer support and peer coach model to initiate and sustain heart-healthy behavioral changes in Veterans.
- Trial name
- HHB (NCT03646656)
- Testing
- reciprocal peer support and non reciprocal coach support
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development